Recombinant Human CCL23 Protein，His

CCL23, also known as chemokine (C-C motif) ligand 23, is a member of the CC chemokine family and plays a critical role in immune responses, particularly in the recruitment and activation of various immune cells. It is primarily secreted by activated monocytes, macrophages, and dendritic cells, and has been implicated in the pathogenesis of several inflammatory diseases and conditions, including rheumatoid arthritis, atherosclerosis, and cancer. Recent studies have highlighted its potential as a therapeutic target and biomarker due to its involvement in pathological processes, including tumor progression and metastasis. The research on recombinant CCL23 protein focuses on its structural characteristics, functional properties, and mechanisms of action within the immune system. By producing recombinant CCL23, scientists aim to explore its biological activities in vitro and in vivo, providing insights into its role in immune modulation. Such studies may advance our understanding of CCL23's involvement in disease mechanisms and pave the way for developing novel therapeutic strategies that utilize CCL23 as a target for intervention in various diseases. Additionally, the production of recombinant CCL23 can facilitate its application in preclinical models, helping to evaluate its potential as a drug candidate or as part of immunotherapy approaches. Therefore, the ongoing research into CCL23 not only deepens our understanding of chemokine biology but also holds promise for innovative treatments in the field of immunology.